{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:38:54Z","timestamp":1776674334204,"version":"3.51.2"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1053,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1186\/s13613-022-01084-8","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T01:02:41Z","timestamp":1676077361000},"page":"8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane\/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial"],"prefix":"10.1016","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02070757","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ignacio","family":"Martin-Loeches","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Wunderink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin H.","family":"Kollef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Huntington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"46","key":"10.1186\/s13613-022-01084-8_bb0010","doi-asserted-by":"crossref","first-page":"1800516","DOI":"10.2807\/1560-7917.ES.2018.23.46.1800516","article-title":"Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017","volume":"23","author":"Suetens","year":"2018","journal-title":"Euro Surveill"},{"issue":"18","key":"10.1186\/s13613-022-01084-8_bb0015","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in US hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1186\/s13613-022-01084-8_bb0020","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1186\/s13613-022-01084-8_bb0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1086\/501795","article-title":"Nosocomial infections in combined medical-surgical intensive care units in the United States","volume":"21","author":"Richards","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"10.1186\/s13613-022-01084-8_bb0030","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","article-title":"Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP\/CAP study","volume":"36","author":"Koulenti","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"10.1186\/s13613-022-01084-8_bb0035","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1164\/rccm.201001-0094OC","article-title":"Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients","volume":"182","author":"Esperatti","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1186\/s13613-022-01084-8_bb0040","doi-asserted-by":"crossref","first-page":"746","DOI":"10.20344\/amp.11607","article-title":"Hospital-acquired pneumonia in a multipurpose intensive care unit: one-year prospective study","volume":"32","author":"Costa","year":"2019","journal-title":"Acta Med Port"},{"key":"10.1186\/s13613-022-01084-8_bb0045","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/infdis\/jiy578","article-title":"Evidence-based study design for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"219","author":"Talbot","year":"2019","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1186\/s13613-022-01084-8_bb0050","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1186\/s13613-022-01084-8_bb0055","doi-asserted-by":"crossref","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1186\/s13613-022-01084-8_bb0060","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-020-03091-2","article-title":"Update of the treatment of nosocomial pneumonia in the ICU","volume":"24","author":"Zaragoza","year":"2020","journal-title":"Crit Care"},{"issue":"1","key":"10.1186\/s13613-022-01084-8_bb0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1183\/09031936.06.00049105","article-title":"Appropriateness and delay to initiate therapy in ventilator-associated pneumonia","volume":"27","author":"Luna","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1186\/s13613-022-01084-8_bb0070","doi-asserted-by":"crossref","unstructured":"American Thoracic Society & Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388\u2013416.","DOI":"10.1164\/rccm.200405-644ST"},{"key":"10.1186\/s13613-022-01084-8_bb0075","doi-asserted-by":"crossref","unstructured":"Juan C, Zamorano L, Perez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother. 2010;54(2):846\u201351.","DOI":"10.1128\/AAC.00834-09"},{"issue":"11","key":"10.1186\/s13613-022-01084-8_bb0080","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/JCM.02357-14","article-title":"In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent US Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum beta-lactamases","volume":"52","author":"Estabrook","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1186\/s13613-022-01084-8_bb0085","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1186\/s13613-022-01084-8_bb0090","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jac\/dkaa049","article-title":"Lung penetration, bronchopulmonary pharmacokinetic\/pharmacodynamic profile and safety of 3 g of ceftolozane\/tazobactam administered to ventilated, critically ill patients with pneumonia","volume":"75","author":"Caro","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1186\/s13613-022-01084-8_bb0095","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/jac\/dks246","article-title":"Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects","volume":"67","author":"Chandorkar","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1186\/s13613-022-01084-8_bb0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"10.1186\/s13613-022-01084-8_bb0105","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1186\/s13613-022-01084-8_bb0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit Care"},{"issue":"8","key":"10.1186\/s13613-022-01084-8_bb0115","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1186\/s13613-022-01084-8_bb0120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1186\/s13613-022-01084-8_bb0125","unstructured":"Clinical and Laboratory Standards Institute. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Tenth Edition ed. Wayne, PA: CLSI; 2015."},{"key":"10.1186\/s13613-022-01084-8_bb0130","doi-asserted-by":"crossref","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707\u201310.","DOI":"10.1007\/BF01709751"},{"issue":"3","key":"10.1186\/s13613-022-01084-8_bb0135","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1198\/sbr.2009.0049","article-title":"Stratified Wilson and Newcombe confidence intervals for multiple binomial proportions","volume":"2","author":"Yan","year":"2010","journal-title":"Stat Biopharm Res"},{"issue":"3","key":"10.1186\/s13613-022-01084-8_bb0140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijantimicag.2018.11.011","article-title":"Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: a systematic review","volume":"53","author":"Heffernan","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1186\/s13613-022-01084-8_bb0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/dku354","article-title":"Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study","volume":"70","author":"Frippiat","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1186\/s13613-022-01084-8_bb0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s13054-021-03773-5","article-title":"Ceftolozane\/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial","volume":"25","author":"Shorr","year":"2021","journal-title":"Crit Care"},{"issue":"8","key":"10.1186\/s13613-022-01084-8_bb0155","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1186\/s13613-022-01084-8_bb0160","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1097\/00003246-200209000-00009","article-title":"Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients","volume":"30","author":"Timsit","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1186\/s13613-022-01084-8_bb0165","first-page":"1","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","volume":"1","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1186\/s13613-022-01084-8_bb0170","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cmi.2019.04.003","article-title":"Is hospital-acquired pneumonia different in transplant recipients?","volume":"25","author":"Gudiol","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1186\/s13613-022-01084-8_bb0175","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ccm.2016.12.005","article-title":"Bacterial pneumonia in patients with cancer: novel risk factors and management","volume":"38","author":"Wong","year":"2017","journal-title":"Clin Chest Med"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-022-01084-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025003280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025003280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01084-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:41:45Z","timestamp":1776670905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025003280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2110582025003280"],"URL":"https:\/\/doi.org\/10.1186\/s13613-022-01084-8","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane\/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-022-01084-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates 2023. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"8"}}